Biosyntech announces changes to board of directors



    LAVAL, QC, Jan. 26 /CNW/ - BioSyntech, Inc. (TSX: BSY), a biotechnology
company developing biotherapeutic thermogels for regenerative medicine, today
announced that Dr. Amine Selmani has resigned from its Board of Directors
effective January 23, 2009. Dr. Selmani is the founder of BioSyntech and was
its Chief Executive Officer from 1995 to 2004 and subsequently Chairman of the
Board of Directors until 2006. He has also managed BioSyntech's broad
intellectual property portfolio since the Company's inception. Dr Selmani will
remain available as an advisor to the Board of Directors.
    "On behalf of the Board of Directors, I would like to thank Dr. Selmani
for his great dedication and contribution to BioSyntech throughout the last 14
years. Dr. Selmani is a pioneer in regenerative medicine and through his
ingenuity and resourcefulness has advanced BioSyntech from academic start-up
to a prominent Canadian public company that is now in the final development
phase for its lead product,- BST-CarGel(R), a highly innovative medical device
that has the potential to significantly improve the way damaged cartilage is
treated," said Michel Lagueux, Chairman of the Board of Directors.
    "It has been my great privilege to work with Michel Lagueux and the new
members of the Board of Directors to ensure that BioSyntech has a clear path
forward. With the Company firmly on the right track, I feel confident that
this is the appropriate time to tenure my resignation from the Board to pursue
other opportunities," said Dr. Selmani. "BioSyntech is concluding enrolment
for the largest randomized clinical trial for cartilage repair ever performed
in North America. We have had to overcome many challenges along the way and I
am very proud that in just a few weeks our long awaited milestone of enrolment
completion for this important trial will be achieved."
    In addition to his direct roles with BioSyntech, Dr. Selmani also helped
create and strengthen the scientific relationship between BioSyntech and Ecole
Polytechnique of Montreal. He played a key role in the establishment of an
industrial research chair for cartilage repair, funded jointly by BioSyntech,
NSERC (Natural Sciences and Engineering Research Council of Canada) and Ecole
Polytechnique. The group of approximately 30 highly skilled researchers, under
the direction of Dr. Michael Buschmann, was awarded more than $30 million in
further funding for infrastructure and state-of-the-art equipment for
cartilage regeneration research.
    BioSyntech will conclude enrolment next month for the Canadian-European
pivotal trial of its cartilage repair device, BST-CarGel(R). To date, the
trial has enrolled more than 70 subjects and participating clinical sites will
be permitted to enrol additional subjects until February 10th, 2009. This
randomized trial compares the treatment of cartilage lesions using
BST-CarGel(R) applied following microfracture to treatment with microfracture
alone. Data is expected in the first quarter of 2010 and results from this
study are intended to support marketing applications in Canada and Europe.

    About BioSyntech

    BioSyntech is a medical device company specialized in the development,
manufacturing and commercialization of advanced biotherapeutic thermogels for
regenerative medicine (tissue repair) and therapeutic delivery. BioSyntech's
platform technology is a family of hydrogels called BST-Gel(R), some of which
are liquid at low temperature and solid at human body temperature. These gels
can be injected or applied to a specific local site and offer beneficial
properties for the local repair of damaged tissue such as cartilage, bone and
chronic wounds and provide the benefit of avoiding invasive surgery. For
additional information, visit www.biosyntech.com.

    Forward-Looking Statements

    This press release contains forward-looking statements and information
which are subject to material risks and uncertainties. Such statements are not
historical facts and are based on the current expectations of management. You
are cautioned that such statements are subject to a multitude of risks and
uncertainties that could cause actual results, future circumstances, or events
to differ materially from those projected in the forward-looking information.
These risks include, but are not limited to, those associated with our
capacity to finance our activities, the adequacy, timing, and results of our
clinical trials, the regulatory approval process, competition, securing and
maintaining corporate alliances, market acceptance of the Company's products,
the availability of government and insurance reimbursements for the Company's
products, the strength of intellectual property, the success of research and
development programs, reliance on subcontractors and key personnel, and other
risks and uncertainties detailed from time-to-time in our filings with the
Canadian securities commissions.
    Readers should not place undue reliance on the forward-looking
information, given that (i) our actual results could differ materially from a
conclusion, forecast or projection in the forward-looking information, and
(ii) certain material factors or assumptions which were applied in drawing a
conclusion or making a forecast or projection as reflected in the
forward-looking information, could prove to be inaccurate. Additional
information about (i) the material factors that could cause actual results to
differ materially from the conclusion, forecast or projection in the
forward-looking information, and (ii) the material factors or assumptions that
were applied in drawing a conclusion or making a forecast or projection as
reflected in the forward-looking information, is contained in the Company's
annual report and other documents filed from time to time with the Canadian
securities commissions which are available at www.sedar.com. These statements
speak only as of the date they are made, and we assume no obligation to revise
such statements as a result of any event, circumstance or otherwise, except in
accordance with law.

    %SEDAR: 00020217EF




For further information:

For further information: James Smith, The Equicom Group, (416) 815-0700
x229, Jsmith@equicomgroup.com

Organization Profile

BIOSYNTECH, INC.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890